Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04113564 · ClinicalTrials.gov registry record · Phase 1
Absolute Oral Bioavailability of Remimazolam
A Phase 1 study, sponsored by Paion UK.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04113564: Completed Phase 1 study, sponsored by Paion UK.
NCT04113564 is a Phase 1 study that has completed, run by Paion UK. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04113564, a Phase 1 study, has completed, sponsored by Paion UK.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
A randomized, open-label, single-dose, 2-way crossover study to compare the relative bioavailability of orally administered remimazolam to an intravenous formulation in healthy volunteers
Primary Outcome
Single-dose bioavailability of an oral formulation of remimazolam relative to an IV formulation of remimazolam in healthy male and female subjects
Interventions
- DRUG Remimazolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-11-03 |
| Est. Completion | 2015-11-20 |
| Phase | Phase 1 |
What the finished NCT04113564 record still lists
NCT04113564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which Remimazolam is the first listed.
NCT04113564 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04113564 about?
NCT04113564 is a clinical study titled "Absolute Oral Bioavailability of Remimazolam". A randomized, open-label, single-dose, 2-way crossover study to compare the relative bioavailability of orally administered remimazolam to an intravenous formulation in healthy volunteers
What is the current status of trial NCT04113564?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2015-11-03. Estimated completion is 2015-11-20.
What interventions are being tested in trial NCT04113564?
The interventions under investigation include: Remimazolam (DRUG).
Who is sponsoring clinical trial NCT04113564?
This trial is sponsored by Paion UK, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04113564's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy